The time has come for big data to live up to its big claims. Are you crying out to see actual applications? Predictive analytics that have led to actionable insight? Proof that it’s all real? Big DiP USA 2014 will give you that proof. Expect to see a line up bursting with good use cases where the results are real. It won’t all be perfect, it’s new after all, so get ready to hear the mistakes and wisdom of hindsight. Plus we’ll bring along the veterans – industries who’ve made a fine art of profiling and targeted marketing. How’ve they done it? And if healthcare can get even half as good as they are, what will that mean for the patient of tomorrow? Join us for a truly thought provoking meeting of minds on 17th & 18th September 2014 in Boston.

1. Big DiP USA 2014 Confidential Draft Agenda
INSPIRING CHANGE TO CREATE A SUSTAINABLE
London  November 2013
[Type a quote from the document or the summary of an interesting point. You can position the text in
Leading Lights from Pharmaceuticals & Beyond
Conference Chairman
Chairman: Marc Berger, Vice President, Real World
Data & Analytics, Pfizer
Confirmed speakers
Sachin Jain, CMIO, Merck
Howard L. Golub, V.P. Clinical Research,
Walgreen Company
John Mattison, Chief Medical Information Officer,
Kaiser Permanente
Martin Leach, Vice President, R&D IT, Biogen Idec
John Reynders, Chief Information Officer, Moderna
Therapeutics
Abel Rajan, Director, Marketing Analytics & Insights,
Novartis
Sebastien Lefebvre, Director R&D IT Platform,
Biogen Idec
Kald Abdallah, Vice President North America
Medical Affairs, Sanofi US
David Vulcano, AVP & Responsible Executive for
Clinical Research, Hospital Corporation America
Karla Miller, AVP Pharmacy Services, Hospital
Corporation America
Michael Weintraub, President & CEO, Co-Founder,
Humedica
Brian Kelly, President, Optum Life Sciences
Dennis Meletiche, Neurology Franchise Head
Global Evidence and Value Development
EMD Serono, Inc
Bryan Takasaki, US Regional Director, R&D IT,
AstraZeneca
Lisa Weiss, Director, Epidemiology, Worldwide
Safety Strategy, Pfizer
Progressing from hype to reality, big theory to big action
The time has come for big data to live up to its big claims. Are you crying out to see actual applications?
Predictive analytics that have led to actionable insight? Proof that it’s all real?
Big DiP USA 2014 will give you that proof. Expect to see a line up bursting with good use cases where the
results are real. It won’t all be perfect, it’s new after all, so get ready to hear the mistakes and wisdom of
hindsight. Plus we’ll bring along the veterans – industries who’ve made a fine art of profiling and targeted
marketing. How’ve they done it? And if healthcare can get even half as good as they are, what will that
mean for the patient of tomorrow?
Join us for a truly thought provoking meeting of minds on 17th
& 18th
September 2014 in Boston.
Sponsored by:

2. Big DiP USA 2014 Confidential Draft Agenda
PRE CONFERENCE WORKSHOPS: 16th
September 2014
Workshop A: Making a business case for a data science center
Workshop B: A light weight approach to big data Fred Trotter, Data
Journalist, DocGraph Journal
Workshop C: Automatic extraction of social taxonomies
Giancarlo Crocetti, Associate Director, Lead Business Consultant I,
Boehringer-Ingelheim
Workshop D: An A-Z on training your workforce in big data skill sets
Confirmed speakers continued
Xiaofeng Zhou, Director, Epidemiology,
Worldwide Safety and Regulatory, Pfizer
Usman Iqbal, Sr. Medical Affairs Leader-
Neuroscience, AstraZeneca
Giancarlo Crocetti, Associate Director, Lead
Business Consultant I, Boehringer-Ingelheim
Fred Trotter, Data Journalist, DocGraph Journal
Steve Labkoff, CEO, Labkoff & Associates
Bioinformatics
Arun Ghosh, Associate Principal, ZS Associates
Alejandro Contreras, Principal, ZS Associates
Invited speakers
Taha A.Kass-Hout, Chief Health Informatics
Officer, FDA
Ken Rudin, Director of Analytics, Facebook
Simon Zhang, Business Analytics Sr. Director,
LinkedIn
Matthew Trunnell, CIO, Broad Institute
Invited speakers continued
Marcus Wilson President, Healthcore
Michele Polz, AVP, Patient Insights &
Analytics, Sanofi
Dr Michael Sills, Vice President of Informatics
Technology, Baylor Quality Alliance
Mark Friedlander, Chief Medical Officer,
Aetna Behavioral Health
Phil Loftus, Chief Information Officer , Aurora
Devavrat Bapat, Director of Supply Chain
Reliability, Johnson & Johnson
Elena Alikhachkina, Director, Multi-Channel
Marketing & Analytics, GlaxoSmithKline
William Shrank, Chief Scientific Officer & Chief
Medical Officer of Provider Innovation and
Analytics, CVS Caremark Corporation
Joel Dudley, Assistant Professor Genetics and
Genomic Sciences, Mount Sinai
Leading lights from the pharmaceutical industry and beyond
Joseph Cacchione, Chair, Operations and
Strategy, Heart and Vascular Institute,
Cleveland Clinic
Jessica Vamathevan, Director CTTV,
GlaxoSmithKline
Thorsten Eickenhorst, Senior Vice President
and Chief Medical Officer, EMD Serono
Luc Verhelst, Head of Information
Technology, European Medicines Agency
Trish Nettleship, Global Director, Social
Media & Influence, UCB Pharma
Lee Guss, Sr. Marketing Manager, Amgen
Christopher J.Frank, VP in the Global
MarketPlace Insights, American Express
John Hendricks,VP/Chief Technology Officer,
Henry Ford Health System
Willis Gee, Director of IT Strategy and
Innovation, Cigna

3. Big DiP USA 2014 Confidential Draft Agenda
Big DiP USA 2014 Day One – 17th
September 2014
8.00am Registration & coffee
8.20am Chairman’s opening remarks Marc Berger, Vice President, Real World Data & Analytics, Pfizer
PLENARY SESSIONS Big data the big picture
8.30
FUTURE INSIGHT
The mind blowing potential of big data: The future brought to life
John Mattison, Chief Medical Information Officer, Kaiser Permanente
9.10
DEBATE
Is big data the key that will unlock real social change across health or
is it just hype?
Sceptics and proponents battle it out to answer the questions: When
will we see big accomplishments? What are the dangers? What will
healthcare look like in 5-10 years time? What role will big data play?
Invited panellists:
Thorsten Eickenhorst, Senior Vice President and Chief Medical
Officer, EMD Serono
Dr Michael Sills, Vice President of Informatics Technology, Baylor
Quality Alliance
10.00 Coffee and networking – followed by delegates selecting which stream they wish to attend
TIME COMMERCIAL CLINICAL & R&D IT
10.30 MARKET ANALYSIS & SEGMENTATION
How to use big data to drive meaningful
segmentation and communication that
leads to commercial outcomes
POST MARKETING TRIALS & SAFTEY
How Walgreens is using big data to facilitate
more efficient post marketing trials
Howard L. Golub, V.P. Clinical Research,
Walgreen Company
Creating a truly innovative holistic system
that captures and channels insights out to
the right people
Sebastien Lefebvre, Director R&D IT
Platform, Biogen Idec
11.10 PANEL SESSION
How big data is being used to driving better
marketing and sales outcomes
Panellists: Abel Rajan, Director, Marketing
Analytics & Strategic Insights, Novartis
BIG DATA IN DRUG DISCOVERY
Project Data Sphere: The dawn of a new era of
collaboration in clinical trial data
Kald Abdallah, Vice President North America
Medical Affairs, Sanofi US
DOUBLE PERSPECTIVE: CLOUD PROVIDER &
PHARMA MANUFACTURER
Venturing into the cloud: One company’s
experience of the speed, security and
overall success
11.50 DOUBLE PERSPECTIVE: MARKETING
AUTOMATION & PHARMA MANUFACTURER
Marketing automation fad or fortune? One
users experience of using a marketing
automation programme
HEALTH PROVIDER INSIGHT
Hospital Corporation America’s data: What
they’ve got, how you can access it, and how
they use it themselves
David Vulcano, AVP & Responsible Executive for
BIG DATA PROVIDER INSIGHT
Update on the development of the big
databases: What are the key challenges and
how’ve they been addressed?

4. Big DiP USA 2014 Confidential Draft Agenda
Clinical Research and Karla Miller, AVP Pharmacy
Services, Hospital Corporation America
12.30 Networking lunch
1.20 Using big data to better understand return
on investment
NIH Collaboratory and big data: Work to-date
and plans for the future
How to set up a data science centre
2.00 PANEL SESSION
The dos and don’ts of communicating big
data insights
Dennis Meletiche, Neurology Franchise
Head, Global Evidence and Value
Development, EMD Serono, Inc
Using NLP where there’s no margin for error:
Strengths and limitations in safety evaluation
Lisa Weiss, Director, Epidemiology, Worldwide
Safety Strategy, Pfizer
Xiaofeng Zhou, Director, Epidemiology,
Worldwide Safety and Regulatory, Pfizer
SEARCH TECHNOLOGY INSIGHT
Obtaining a 360º view: What that will bring
to your big data analytics
2.40
PANEL SESSION
Personalised medicine vs real world
evidence: Enemies or symbiotic partners?
Invited panellists:
Brian Sweet, Executive Director, Healthcare
Alliances, AstraZeneca
PANEL SESSION
The use of shared vocabularies and taxonomies
in the pursuit of accelerated clinical research
Facilitator: Steve Labkoff, CEO, Labkoff &
Associates Bioinformatics
Invited panellists: Tom Plasterer, AstraZeneca
SECURITY SESSION
Governance & structure for big data: What
are the rules of engagement?
3.20 Afternoon coffee & networking
PLENARY SESSIONS Exploring the possibilities
3.50
STREAM SUMMARY The chairpersons from the three streams will be
invited to the stage to summarize the key outcomes of their stream.
Commercial stream: Alejandro Contreras, Principal, ZS Associates
4.10
The holy grail union of clinical and claims: Explore the possibilities this
novel class of real world data presents
Michael Weintraub, President & CEO, Co-Founder, Humedica
Brian Kelly, President, Optum Life Sciences
4.40
BIG DATA BIG EXAMPLE
Building a digital Biotech John Reynders, Chief Information Officer, Moderna Therapeutics
5.15
PANEL SESSION
What’s going to unlock the most powerful results: Hypothesis driven
questioning vs emergent insights?
Panellists: John Reynders, Chief Information Officer, Moderna
Therapeutics
Sebastien Lefebvre, Director R&D IT Platform, Biogen Idec
5.50 DRINKS RECEPTION & DINNER AT 7PM

5. Big DiP USA 2014 Confidential Draft Agenda
Big DiP USA 2014 Day Two – 18th
September 2014
8.00am Registration & coffee
8.20am Chairman’s opening remarks Marc Berger, Vice President, Real World Data & Analytics, Pfizer
PLENARY SESSIONS Big data the big picture
8.30
CROSS INDUSTRY INSPIRATION A provocative and creative approach to
questioning the data – with powerful results
Invited speaker: Alex Laing, Director of Analytics Platform & Delivery
(APD) Team, eBay
9.10
STRATEGIC PANEL
How to structure your business to keep ahead of the big data
paradigm shift
Panellists:
Martin Leach, Vice President, R&D IT, Biogen Idec
Sachin Jain, CMIO, Merck
10.00 Coffee and networking – followed by delegates selecting which stream they wish to attend
TIME HOW PAYERS & REGULATORS USE BIG DATA MAKING BIG DATA CREDIBLE & UNDERSTANDABLE NEW DATA SOURCES
10.40 PAYER PERSPECTIVE
Big data through the eyes of the payer:
Insight into their methods, insights and
outcomes
Invited speaker: Mark Friedlander, Chief
Medical Officer, Aetna Behavioral Health
CROSS INDUSTRY INSPIRATION
Starting with a universe, finishing with
manageable data – How to refine it and know
what’s good enough
Invited speaker: Simon Zhang, Business
Analytics Sr. Director, LinkedIn
Hacking healthcare data for the greater
good: The latest open source revelation
Fred Trotter, Data Journalist, DocGraph
Journal
11.20 ACO PERSPECTIVE
Using big data to meet cost, quality and
marketing objectives
PANEL SESSION
Deep vs diverse: What delivers the best
results?
Bryan Takasaki, US Regional Director, R&D IT,
AstraZeneca
John Reynders, Chief Information Officer,
Moderna Therapeutics
Uncover the data opportunity represented
by PCORI and the patient centred networks
12.00 FDA update: Big data initiatives in the drug
development safety processes
Integrating disparate, unstructured content
from multiple sources
Unearthing off-the-wall data sources:
Thinking creatively to find the right data
12.40 Networking lunch
1.40 Getting the right balance to meet HIPAA
standards and still work creatively with your
The application of BIG data in the context of
Real World Evidence (RWE): Methodological
QUICK FIRE INSIGHTS & DISCUSSION
Personal monitoring technology might

6. Big DiP USA 2014 Confidential Draft Agenda
data challenges and unlocking of opportunities
Usman Iqbal, Sr. Medical Affairs Leader-
Neuroscience, AstraZeneca
herald a new era of personalised medicine,
but how can we amalgamate this data and
make it meaningful? How can we connect
the dots between the patient, the physician,
and industry? What’s going to rise to the
surface?
2.20 New discoveries fuelled by social media
listening: How data drove real usable
customer insights
Let your data tell a story, paint a picture:
Creative visualization techniques
QUICK FIRE INSIGHTS & DISCUSSION
Uncover the freshest international data
sources: What’s out there and what’s it
good for?
Five data providers from various countries
across the world will summarise their
offering, followed by the chance for you to
question the intricacies of their databases
and the difference between them.
3.00
PANEL SESSION
How to use social media without opening up
Pandora’s box of FDA compliance headaches:
Update on FDA positioning followed by
discussion
Big data and research: How big data will
change the way we think and research
Giancarlo Crocetti, Associate Director, Lead
Business Consultant I, Boehringer-Ingelheim
3.40 Afternoon coffee & networking
PLENARY SESSIONS
4.10
STREAM SUMMARY
The chairpersons from the three streams will be invited to the stage to
summarize the key outcomes of their stream. Questions from the floor.
4.30
FDA & EMA UPDATES
FDA big data plans unveiled: What to expect
EMA plans: Including new publicly accessible EU clinical trials register
Invited speaker:
Taha A.Kass-Hout, Chief Health Informatics Officer, FDA
Luc Verhelst, Head of Information Technology, EMA
5.10
A BIG DATA BIG EXAMPLE
How we used big data to create actionable insights that led to a direct
patient impact
5.40
PANEL SESSION
How can we incorporate patient centricity into big data?
Panellists include: Usman Iqbal, Sr. Medical Affairs Leader-
Neuroscience, AstraZeneca
6.00 Chairman’s closing remarks and end of conference